CME RULE: 413. SUMMARY ACCESS DENIAL ACTION
A. Authority to Deny Access
Non-members may be denied access to any or all CME Group markets or be denied access to the Globex platform or any other electronic trading or clearing platform owned or controlled by CME Group by the Chief Regulatory Officer or his delegate upon a good faith determination that there are substantial reasons to believe that such immediate action is necessary to protect the best interests of the Exchange.
On June 30, 2010, CME Group’s Market Regulation Department, through its Chief Regulatory Officer, summarily denied Marat Yunusov I Ayrat Yunusov direct and indirect access to all CME Group markets, including the CME Globex electronic trading platform, all trading floors owned or controlled by CME Group, and all clearing platforms owned or controlled by CME Group. The summary access denial prohibits trading, placing orders, and controlling or directing the trading for any person or entity in any CME Group product. The summary access denial further prohibits the affiliation or business dealings with any member or member firm of CME, CBOT, NYMEX or COMEX.
This action is based on a good faith determination that on June 3 and 4, 2010, accounts in the names of Marat Yunusov and Ayrat Yunusov executed 943 non-bona fide transactions opposite each other in the E-Micro British Pound and Russian Ruble futures contracts, the effect of which created a multi-million dollar profit in the account in the name of Ayrat Yunusov, and a corresponding debit in the account in the name of Marat Yunusov, which Marat Yunusov is unable to satisfy.
Accordingly, there are substantial reasons to believe that such immediate action is necessary to protect the best interests of the exchanges and the marketplace.
Pursuant to Rule 413, this access denial will remain in effect for 60 days, commencing immediately and continuing through and including September 5, 2010.
July 7, 2010
Register for regular updates here and manage your email preferences.